The Phase II study DESTINY-Lung trial showed encouraging results, with T-DXd demonstrating an ORR of 55% and mPFS of 8.2 months in previously treated patients with HER2-mutated NSCLC. Here, ERBB2 is linked to non-small cell lung carcinoma.